Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Melasma: Etiology and Diagnosis
Description
In this presentation on melasma, Dr. Kavita Mariwala, a board-certified dermatologist, discusses the etiology and diagnosis of the condition. She emphasizes the importance of accurately diagnosing facial hyperpigmentation, warning against hastily labeling it as melasma without proper evaluation. Different causes of hyperpigmentation are highlighted, including drug-induced changes and specific patterns seen in patients from diverse backgrounds. Dr. Mariwala describes the pathogenesis of melasma, noting increased melanogenesis, altered skin barrier function, and the role of vascular components. She advocates for a multifaceted treatment approach that addresses various aspects of melasma rather than merely targeting pigmentation. Sunshine protection is stressed as essential, alongside the use of topical lighteners. The importance of cycling treatments to enhance efficacy and minimize side effects is discussed, particularly concerning the usage of hydroquinone and tranexamic acid. The speaker also introduces newer compounds like thiamidol and isobionic amide, which can effectively treat melasma without unwanted side effects. She also briefly touches on the utility of antioxidants and vascular lasers in treating aspects of melasma. Ultimately, Dr. Mariwala concludes that understanding the 360-degree nature of melasma is crucial for effective management, echoing the sentiment that treatment success often requires long-term commitment, similar to managing chronic conditions.
View moreConclusions
- Melasma is often misdiagnosed when patients present with facial hyperpigmentation.
- Skin of color patients may have different causes of hyperpigmentation that mimic melasma, such as Hori Nevus or post-inflammatory hyperpigmentation.
- The pathogenesis of melasma involves increased melanogenesis, altered barrier function, and vascular components.
- A comprehensive approach to treating melasma involves addressing each component of the melasma cycle, not just targeting pigmentation.
- Effective melasma treatment requires a combination of agents targeting melanocyte activation, melanin production, and distribution.
- Photo protection is crucial for managing melasma and should be a routine practice for patients.
- Emerging agents such as thiamidol and isobionic amide show promise in treating melasma without adverse effects associated with traditional lighteners.
- Tranexamic acid can be effective in melasma treatment, but optimal dosing remains under investigation, with daily dosing strategies showing promise.
- Incorporating antioxidants and considering mast cell involvement may provide additional benefits in managing melasma.
- Laser therapy, including Picosecond and QS Nd:YAG lasers, has shown efficacy in treating melasma, especially in cases with underlying vascular components.
- Artzi O, et al. J Cosmet Dermatol. 2021;20:2102-2107
- Guevara IL, Pandya AG. Int J Dermatol 2001;40:210
- Zhu CY, Li Y, Sun QN, Takada A, Kawada A. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019 Feb 1;29(1):55-58
- Chowdhary B, Mahajan VK, et al. Therapeutic efficacy and safety of oral tranexamic acid 250 mg once a day versus 500 mg twice a day: a comparative study. Arch Dermatol Res. 2021 Mar;313(2):109-117.
- Karrabi M, Ali Mansournia M, et al. Clinical evaluation of efficacy and tolerability of cysteamine 5% cream in comparison with tranexamic acid mesotherapy in subjects with melasma: a single-blind, randomized clinical trial study. Arch Dermatol Res 2021 Sep;313(7):539-547.
- Polnikorn N, et al. Dermatol Surg. 2020;46:1651-1656.
- Geddes ER, et al. Lasers Surg Med. 2017;49:20-26.